Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently amended) A compound of formula I

wherein

X is $=CR^0$ - or =N-;

each of R⁰, R¹, R², R³ and R⁴ independently is hydrogen; hydroxy; C₁-C₈alkyl; C₂-C₈alkenyl;

 $C_3-C_8 cycloalkyl; C_3-C_8 cycloalkyl-C_1-C_8 alkyl; hydroxyC_1-C_8 alkyl; C_1-C_8 alkyl; C_1-C_8 alkyl; hydroxyC_1-C_8 alkyl; arylC_1-C_8 alkyl; arylC_1-C_8 alkyl; which optionally may be substituted on the ring by hydroxy, <math>C_1-C_8 alkoxy$, carboxy or $C_1-C_8 alkoxy$ carboxyl;

or R³ and R⁴ form together with the nitrogen and carbon atoms to which they are attached a 5 to 10 membered heterocyclic ring and having 1, 2 or 3 heteroatoms selected from N, O and S;

or each of R^1 , R^2 and R^3 , independently, is halogen; halo- C_1 - C_8 alky; C_1 - C_8 alkoxy; halo- C_1 - C_8 alkoxy; hydroxy C_1 - C_8 alkoxy; C_1 - C_8 alkoxy C_1 - C_8 alkoxy; aryl; aryl C_1 - C_8 alkoxy; heteroaryl; heteroaryl- C_1 - C_4 alkyl; 5 to 10 membered heterocyclic ring; nitro; carboxy;

 $C_2-C_8 alkoxy carbonyl; \ C_2-C_8 alkyl carbonyl; \ -N(C_1-C_8 alkyl)C(O) \ C_1-C_8 alkyl; \ -N(R^{10})R^{11};$

 $-CON(R^{10})R^{11}; -SO_2N(R^{10})R^{11}; \ or \ -C_1-C_4-alkylene-SO_2N(R^{10})R^{11}; \ wherein each of \ R^{10} \ and \ R^{11} \ independently is hydrogen; \ hydroxy; \ C_1-C_8alkyl; \ C_2-C_8alkenyl; \ C_3-C_8cycloalkyl;$

 C_3 - C_8 cycloalkyl- C_1 - C_8 alkyl; C_1 - C_8 alkoxy C_1 - C_8 alkyl; hydroxy C_1 - C_8 alkyl; hydroxy C_1 - C_8 alkyl; (C_1 - C_8 alkyl)-carbonyl; aryl C_1 - C_8 alkyl which optionally may be substituted on the ring by hydroxy, C_1 - C_8 alkoxy, carboxy or C_2 - C_8 alkoxycarbonyl; or 5 to 10 membered heterocyclic ring;

or R¹ and R² form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl group having one or two heteroatoms selected from N, O and S; or

R⁵ independently is hydrogen; halogen; cyano; C₁-C₀alkyl; halo-C₁-C₀alkyl;

 C_2 - C_8 alkenyl; C_2 - C_8 alkynyl; C_3 - C_8 cycloalkyl; C_3 - C_8 cycloalkyl C_1 - C_8 alkyl; C_5 - C_{10} aryl C_1 - C_8 alkyl;

R⁸ is hydrogen;

each of R⁷, R⁸ and R⁹ is independently hydrogen; hydroxy; C₁-C₀alkyl; C₂-C₀alkenyl;

halo- C_1 - C_8 alkyl; C_1 - C_8 alkoxy; C_3 - C_8 cycloalkyl; C_3 - C_8 cycloalkyl C_1 - C_8 alkyl; aryl C_1 - C_8 alkyl;

-Y-R¹² wherein Y is a direct bond or O and R¹² is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring having 1, 2 or 3 heteroatoms selected from N, O and S; carboxy; (C₁-C₈alkoxy)-carbonyl; -N(C₁₋₈alkyl)-CO-NR¹⁰R¹¹; -CONR¹⁰R¹¹; -N(R¹⁰)(R¹¹); or R⁷ and R⁸ or R⁸ and R⁹, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl having 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring;

provided that one of R1, R2 or R3 is -CON(R10)R11 or-SO2N(R10)R11;

in free form or salt form;

wherein

aryl represents phenyl, naphthyl or 1,2,3,4-tetrahydronaphthyl,

heteroaryl is a 5 or 6 membered aromatic heterocyclic ring, optionally condensed to 1 or 2 benzene rings and/or to a further heterocyclic ring, and

wherein a heterocyclic ring is a 5 or 6 membered heterocyclic ring being saturated or unsaturated and optionally condensed to 1 or 2 benzene rings and/or to a further heterocyclic ring.

2. (Original) A process for the production of a compound of formula I according to claim 1, comprising the steps of reacting a compound of formula II

wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and X are as defined in claim 1, and Y is a leaving group; with a compound of formula III

$$R^7$$
 R^8
 R^9
 -3

wherein R7, R8 and R9 are as defined in claim 1;

and recovering the resulting compound of formula I in free form or in salt form, and, where required, converting the compound of formula I obtained in free form into the desired salt form, or vice versa.

- 3. (Canceled)
- 4. (Original) A pharmaceutical composition comprising a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers or diluents therefor.
- 5-7 (Canceled)
- 8. (Previously Presented) A method for treating breast cancer, comprising: administering to a subject in need thereof, a therapeutically effective amount of the compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof.
- 9. (Cancelled)